Preclinical development ofAMG139, a human antibody specifically targetingIL‐23
British Journal of Pharmacology2014Vol. 172(1), pp. 159–172
Citations Over TimeTop 21% of 2014 papers
Kathleen Köck, W. Pan, Jason M. Gow, Michelle Horner, John P. Gibbs, Alex Colbert, Theresa J. Goletz, Kathryn J. Newhall, William A. Rees, Y. Sun, Y Zhang, Jordan C. O’Neill, Amber Umble-Romero, Samantha P. Prokop, C D Krill, Liliana Som, Sabina Buntich, M W Trimble, Wayne Tsuji, Jennifer E. Towne
Abstract
The in vitro pharmacology, PK, immunogenicity and safety characteristics of AMG 139 in cynomolgus monkeys support its continued clinical development for the treatment of various inflammatory diseases.
Related Papers
- An overview of scientific and regulatory issues for the immunogenicity of biological products.(2003)
- → Immunogenicity of Therapeutic Proteins(2010)29 cited
- → Guidance on Immunogenicity Assessment of Biologically Derived Therapeutic Proteins: A European Perspective(2011)4 cited
- [An experimental study of the immunogenicity of Pseudomonas aeruginosa vaccines].(1976)
- → Immunogenicity(2015)